United Therapeutics (UTHR) Shares Outstanding (Weighted Average) (2009 - 2026)

United Therapeutics has disclosed Shares Outstanding (Weighted Average) across 18 years of filings, most recently posting $43.5 million for Q1 2026.

• Shares Outstanding (Weighted Average) for Q1 2026 came in at $43.5 million, down 3.12% year-over-year; the trailing twelve-month figure through Mar 2026 was $43.5 million (down 3.12% YoY), and the FY2025 annual result was $44.3 million, down 1.99% from the prior year.
• Shares Outstanding (Weighted Average) came in at $43.5 million for Q1 2026 at United Therapeutics, down from $44.3 million in the prior quarter.
• In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $47.0 million in Q1 2024 to a low of $43.5 million in Q1 2026.
• The 5-year median for Shares Outstanding (Weighted Average) is $45.3 million (2022), against an average of $45.5 million.
• Across the five-year window, Shares Outstanding (Weighted Average) increased 3.3% in 2023 and decreased 4.5% in 2024, its largest moves.
• United Therapeutics' Shares Outstanding (Weighted Average) stood at $45.5 million in 2022, then advanced by 2.86% to $46.8 million in 2023, then dropped by 3.42% to $45.2 million in 2024, then slipped by 1.99% to $44.3 million in 2025, then dropped by 1.81% to $43.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $43.5 million (Q1 2026), $44.3 million (Q4 2025), and $44.6 million (Q3 2025), per Business Quant data.